Genzyme Transgenics Corporation

Genzyme Corporation

Gtc Biotherapeutics, Inc.

Genzyme Transgenic Corporation

Genzyme Transgenics Corporatiion

Paul Ditullio

Harry M Meade

Edward S Cole

Daniel Pollock

Seng H Cheng

Alan E Smith

Karl M Ebert

This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GalNAc) along with fucose, N-acetylglucosamine, galactose, mannose, and N-acetylneuraminic acid/N-glycolyneuraminic acid. The monosaccharide composition differs with that of plasma derived ATIII (phATIII). It has been found that tgATIII has an increased clearance rate when compared to phATIII.

Treatments using transgenic goat produced antithrombin III

This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GaINAc) along with fucose, N-acetylglucosamine, galactose, mannose, and N-acetylneuraminic acid/N-glycolyneuraminic acid. The monosaccharide composition differs with that of plasma derived ATIII (phATIII). It has been found that tgATIII has an increased clearance rate when compared to phATIII.

Transgenically produced Antithrombin III

A method for the production of monoclonal antibodies in mammal's milk through the creation of transgenic animals that selectively express foreign antibody genes in mammary epithelial cells.

Transgenic production of antibodies in milk

Transgenically produced antithrombin III

A method for the production of monoclonal antibodies in mammal's milk, through the creation of transgenic animals that selectively express foreign antibody genes in mammary epithelial cells.

A DNA comprising at least one inactivated hormone responsive element and a nucleic acid sequence encoding a membrane-associated protein is described. Therapeutic compositions and cells including the DNA are also described. Other aspects of the invention include methods of treating subjects having cystic fibrosis which include administering an effective amount of the DNA to subjects having cystic fibrosis such that functional cystic fibrosis transmembrane conductance regulator is produced by the subject at a level which is not detrimental to the subject. The present invention also pertains to a method of introducing the DNA into a cell such that the membrane-associated protein is produced at a level which is not detrimental to the cell and cells produced by this method. Still other aspects of the invention include a method of assaying DNA for the presence or absence of a hormone responsive element in a species in which the hormone responsive element is functional and a method of selectively breeding female transgenic mammals which produce a protein of interest.

Growing community of inventors

Framingham, MA, United States of America

Paul Ditullio